Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2022-06-13
|
| gptkbp:ATCCode |
N07XX18
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
solution for injection
25 mg/0.5 mL |
| gptkbp:frequency |
once every 3 months
|
| gptkbp:genericName |
gptkb:vutrisiran
|
| https://www.w3.org/2000/01/rdf-schema#label |
AMVUTTRA
|
| gptkbp:indication |
hereditary transthyretin-mediated amyloidosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
injection site reaction
dyspnea arthralgia |
| gptkbp:target |
gptkb:transthyretin_mRNA
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_ALNY
|
| gptkbp:bfsLayer |
7
|